Homocysteine

← Back to Lab Reference Library

Category: Inflammation & Cardiovascular  |  Also known as: HCY, Total Homocysteine, Plasma Homocysteine  |  Sample: Plasma or serum; fasting preferred; place on ice immediately after draw

1. What This Test Measures

Homocysteine is a sulfur-containing amino acid that arises as an obligate intermediate in methionine metabolism. Methionine, obtained from dietary protein, is activated to S-adenosylmethionine (SAM), the universal methyl donor for hundreds of methylation reactions throughout the body, from DNA methylation to neurotransmitter synthesis to phospholipid production. When SAM donates its methyl group to a substrate, it becomes S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine.

Homocysteine then faces one of two metabolic fates, both of which require adequate B vitamins:

• Remethylation to methionine: requires methylcobalamin (B12) as a cofactor and 5-methyltetrahydrofolate (5-MTHF, active folate) as the methyl donor, via the methionine synthase enzyme. This pathway regenerates methionine and returns the methyl group to the cycle, restoring SAM production. Betaine (trimethylglycine) provides an alternative methyl group for remethylation via betaine-homocysteine methyltransferase (BHMT) in the liver.
• Transsulfuration to cystathionine: requires pyridoxal-5-phosphate (active vitamin B6) as a cofactor, via cystathionine beta-synthase (CBS). This pathway ultimately produces cysteine, which is required for glutathione synthesis, the body's primary intracellular antioxidant. Homocysteine cleared through transsulfuration is not available for remethylation.

When either pathway is impaired by B vitamin deficiency, MTHFR gene variants, enzyme dysfunction, or excessive methionine load, homocysteine accumulates in the bloodstream. Total homocysteine measures all forms (free and protein-bound) in the plasma.

2. Why This Test Matters

• Cardiovascular risk marker: elevated homocysteine independently predicts coronary artery disease, stroke, peripheral arterial disease, and cardiovascular mortality. The Homocysteine Studies Collaboration meta-analysis (over 30 prospective studies, 5,000+ cardiovascular events) found that a 5 µmol/L lower homocysteine was associated with 20% lower coronary heart disease risk and 59% lower stroke risk. Risk rises continuously from homocysteine above 6 to 7 µmol/L, well below the conventional threshold of 15 µmol/L.
• Methylation status indicator: elevated homocysteine is the most clinically accessible functional indicator of impaired methylation capacity. When homocysteine rises, SAM production falls, impairing methylation reactions critical for: DNA methylation (epigenetic regulation), neurotransmitter synthesis (dopamine, serotonin, norepinephrine, creatine production), phosphatidylcholine production (cell membrane integrity), and detoxification pathway support.
• Functional B vitamin deficiency indicator: homocysteine elevation typically precedes overt hematological B vitamin deficiency signs (macrocytosis, anemia) by months to years, making it the earliest functional indicator that B12 and folate status is insufficient for methylation needs even when serum B12 and folate appear borderline normal.
• Cognitive and dementia risk: elevated homocysteine is one of the most consistently replicated modifiable risk factors for Alzheimer's disease and vascular dementia. Multiple prospective studies show that homocysteine above 14 µmol/L doubles dementia risk, and B vitamin supplementation that normalizes homocysteine slows brain atrophy in elderly individuals with mild cognitive impairment in RCTs.
• Endothelial damage mechanism: homocysteine directly damages endothelial cells through oxidative stress, reduces nitric oxide bioavailability (impairing vasodilation), promotes LDL oxidation, stimulates smooth muscle cell proliferation, and impairs fibrinolysis, collectively driving atherosclerosis and thrombosis risk.

3. Standard Lab Reference Range

Homocysteine Level	Standard Classification
Below 15 µmol/L	Normal (standard reference)
15 to 30 µmol/L	Mild hyperhomocysteinemia
30 to 100 µmol/L	Moderate hyperhomocysteinemia
Above 100 µmol/L	Severe hyperhomocysteinemia (homocystinuria)

The standard threshold of 15 µmol/L was established to detect homocystinuria, a rare metabolic disorder, not to identify the cardiovascular risk range. Cardiovascular risk begins rising at approximately 6 to 7 µmol/L, making the standard normal range clinically misleading for the purpose of cardiovascular risk assessment and methylation monitoring.

4. Optimal Functional Medicine Range

Homocysteine Level	Functional Interpretation
Below 6 µmol/L	Ideal: lowest cardiovascular and cognitive risk; excellent methylation cycle function
6 to 7 µmol/L	Optimal: low risk; maintain with B vitamin adequacy
7 to 9 µmol/L	Borderline: measurable risk elevation beginning; assess B12, folate, B6, and MTHFR
9 to 15 µmol/L	Elevated: significant cardiovascular and cognitive risk; B vitamin repletion indicated
Above 15 µmol/L	High: marked risk; aggressive B vitamin therapy; evaluate for severe B deficiency, MTHFR, kidney disease

5. Causes of Elevated Homocysteine

• Vitamin B12 deficiency: the most common cause; methylcobalamin is required for the methionine synthase enzyme to remethylate homocysteine; B12 deficiency from dietary inadequacy, pernicious anemia, metformin use, PPI use, or aging causes progressive homocysteine accumulation
• Folate deficiency: 5-methyltetrahydrofolate is the methyl donor for homocysteine remethylation; folate deficiency from poor diet, alcohol use, malabsorption, or medications (methotrexate) elevates homocysteine
• MTHFR gene variants: C677T and A1298C reduce the enzyme that produces active 5-MTHF from folate by 30 to 70%; impair the efficiency of homocysteine remethylation; particularly important when folate and B12 appear borderline adequate but homocysteine is still elevated
• Vitamin B6 deficiency: pyridoxal-5-phosphate is required for the transsulfuration pathway (CBS enzyme); B6 deficiency impairs homocysteine clearance through the cystathionine pathway
• Chronic kidney disease: the kidneys clear homocysteine; reduced GFR from CKD allows homocysteine to accumulate; homocysteine above 15 to 20 µmol/L in the context of CKD reflects both reduced clearance and reduced methylation capacity
• Hypothyroidism: reduces glomerular filtration and impairs methylation enzyme function; even subclinical hypothyroidism (TSH above 2.5) is associated with modestly elevated homocysteine
• Medications: methotrexate (folate antagonist), metformin (reduces B12), phenytoin and other anticonvulsants (impair folate metabolism), nitrous oxide (inactivates B12), and estrogen-containing oral contraceptives (lower B6 levels) all raise homocysteine
• High methionine intake: excess dietary methionine (from high protein intake, particularly animal protein) without adequate B vitamins to support its catabolism can transiently elevate homocysteine
• Aging: B vitamin absorption declines with age; GFR declines; homocysteine rises progressively with age in most individuals without targeted supplementation

6. How to Lower Homocysteine

7. Homocysteine and MTHFR: The Practical Clinical Approach

Scenario	Homocysteine	B12	Folate	MTHFR	Recommended Approach
B12 deficiency dominant	Elevated	Low	Normal	Any	Methylcobalamin primary; add methylfolate; recheck in 8 weeks
Folate deficiency dominant	Elevated	Normal	Low RBC	Any	Methylfolate primary; add methylcobalamin; recheck in 8 weeks
MTHFR-driven	Elevated	Normal	Normal serum (but impaired conversion)	C677T or A1298C	Switch folic acid to methylfolate; add riboflavin; add TMG if persistent
CKD-associated	Elevated	Normal	Normal	Any	High-dose B vitamins may help partially; kidney protection is primary
Medication-induced	Elevated	Borderline (metformin)	Low (methotrexate)	Any	B12 for metformin; leucovorin for methotrexate; review medication necessity

8. Related Lab Tests

9. When Testing Is Recommended

• Cardiovascular risk stratification: homocysteine adds independent risk information beyond standard lipid panels
• Cognitive health and dementia prevention assessment: elevated homocysteine is one of the most consistently modifiable dementia risk factors
• Functional B12 and folate adequacy assessment: more sensitive than serum levels alone for identifying functional deficiency
• MTHFR variant follow-up: confirms whether the variant is producing functional methylation impairment
• Patients on metformin, methotrexate, or other folate/B12-depleting medications
• Vegans and strict vegetarians: high B12 deficiency risk from dietary limitation
• Adults over 60: age-related B vitamin absorption decline and GFR reduction raise homocysteine progressively
• Personal or family history of premature cardiovascular disease, stroke, or venous thromboembolism
• Recurrent miscarriage: elevated homocysteine is associated with adverse pregnancy outcomes including early pregnancy loss
• Chronic kidney disease: homocysteine accumulates with declining GFR and adds independent cardiovascular risk

10. Clinical Perspective

11. Frequently Asked Questions